Related Experiment Video
Updated: Oct 23, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
929
COVID-19 and coagulopathy
Malay Sarkar1, Irappa V Madabhavi2,3,4, Pham Nguyen Quy5
1Department of pulmonary medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
The Clinical Respiratory Journal
|August 16, 2021
Summary
This review examines COVID-19-associated coagulopathy, exploring its epidemiology, mechanisms, and treatment. Understanding thrombosis risk in COVID-19 is crucial for patient management.
Area of Science:
- Infectious Diseases
- Hematology
- Critical Care Medicine
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a global pandemic, overwhelming healthcare systems.
- COVID-19 infection is linked to an increased risk of thromboembolic complications.
- The high thrombotic risk in COVID-19 patients stems from inflammation, endotheliitis, hyperviscosity, and hypercoagulability.
Purpose of the Study:
- To review the epidemiology of COVID-19-associated coagulopathy.
- To explore the clinical features and underlying mechanisms of thrombosis in COVID-19.
- To summarize current treatment strategies for COVID-19-related coagulopathy.
Main Methods:
- A comprehensive literature search was conducted.
- Databases searched included PubMed, EMBASE, and CINAHL.
- Search terms comprised COVID-19, coagulopathy, and thrombosis, covering January 2020 to December 2020.
Main Results:
- COVID-19 is associated with significant coagulopathy and thrombosis.
- Multiple pathophysiological mechanisms contribute to this heightened thrombotic risk.
- Epidemiological and clinical data highlight the severity of these complications.
Conclusions:
- COVID-19-associated coagulopathy presents a major clinical challenge.
- Further research into mechanisms and treatments is warranted.
- Effective management strategies are essential for improving outcomes in affected patients.
Related Concept Videos
01:06Coagulation
490
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
490
01:09Coagulation
8.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
01:24Disorders of Hemostasis
1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
02:45Blood Transfusion and Agglutination
11.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.9K